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Most patients with type 2 diabetes mellitus (T2DM) administer
insulin twice daily, yet many use premixed insulin
preparations (Lilly Health, data on file). Premixtures of short-
or rapid-acting and intermediate-acting insulins twice daily are
commonly used, offering convenience and increased dosing
accuracy compared with insulins mixed from separate vials. 1
Injection of human insulin mixtures is recommended 30 - 45
minutes pre-meal to control postprandial blood glucose (BG).2
In contrast, manufactured mixtures containing rapid-acting
insulin lispro offer the convenience and accurate dosing of a
premixed formulation plus immediate pre-meal or post-meal
injection.
A manufactured mixture, 25% insulin lispro and 75% neutral
protamine lispro (NPL) (Humalog Mix25, Humalog Mix 75/25
in the USA(Mix25)) has been  approved for clinical use in most
countries. The intermediate-acting insulin within these
mixtures consists of a crystalline suspension of insulin lispro-
protamine crystals referred to as NPL. The activity profile of
NPLis similar to that of neutral protamine Hagedorn (NPH).3
NPLis used since an exchange between soluble insulin lispro
and protamine-bound human insulin occurs with prolonged
storage of insulin lispro-NPH mixtures. 
Compared with human insulin mixtures, Mix25
administered twice daily in T2DM patients results in improved
postprandial glycaemic control, similar overall glycaemic
control, less risk of nocturnal hypoglycaemia, and the
convenience of dosing immediately before (or after) meals.4-7
Nevertheless, the pharmacodynamic profile of Mix25
compared with human insulin has not been investigated over
several days in a controlled clinical setting in T2DM patients.
The present pilot study compared the effects of Mix25 and
human insulin 30/70 (30/70) on 24-hour plasma glucose (PG)
profiles during 3 days of an inpatient test phase and frequency
of hypoglycaemia throughout the study in T2DM patients.
Methods
Patient population
All patients eligible for the study had T2DM according to
World Health Organisation (WHO) criteria, 8 were aged 40 - 70
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Objective. To compare the effects of Humalog Mix25
(Humalog Mix75/25 in the USA) (Mix25) and human insulin
30/70 (30/70) on the 24-hour inpatient plasma glucose (PG)
profile in patients with type 2 diabetes mellitus (T2DM).
Design. A randomised, open-label, 8-week crossover study.
Study insulins were injected twice daily, 5 minutes before
breakfast and dinner.
Setting. Four-week outpatient (dose-adjustment) treatment
phase, and 3-day inpatient (test) phase. 
Patients. Twenty-five insulin-treated patients with T2DM
(ages 40 - 66 years), mean (± standard error of the mean)
(SEM) HbA1c 7.7% ± 0.23%, and body mass index (BMI) 29.3
± 0.83 kg/m2.
Outcome measures. 24-hour PG profiles, PG excursions after
meals, PG area under the curve (AUC), and 30-day
hypoglycaemia rate.
Results. The 2-hour PG excursions following breakfast (5.5 ± 
0.34 v. 7.2 ± 0.34 mmol/l, p = 0.002) and dinner (2.4 ± 0.27 v.
3.4 ± 0.27 mmol/l, p = 0.018) were smaller with Mix25 than
with 30/70. PG AUC between breakfast and lunch was
smaller with Mix25 than with 30/70 (77.6 ± 3.8 v. 89.5 ± 4.3
mmol/h/ml, p = 0.001). PG AUC between lunch and dinner,
dinner and bedtime, and bedtime and breakfast did not differ
between treatments. Pre-meal and nocturnal PG were
comparable. The postprandial insulin requirement for lunch
meals was supplied equally by the two insulin treatments.
The thirty-day hypoglycaemia rate was low (Mix25 0.049 ±
0.018 v. 30/70 0.100 ± 0.018 episodes/patient/30 days, p =
0.586) for both treatments.
Conclusion. In patients with T2DM, Mix25 improved the 24-
hour PG profile with lower postprandial PG excursions than
with human insulin 30/70.
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years, and had a haemoglobin A1C (HbA1C) < 10% (local
laboratory normal reference range 4.4 - 6.4%). They had been
treated with human insulin 30/70 twice daily and practised
self-monitoring of BG for at least 3 months before the study.
Patients were excluded if they usually injected human insulin
30 - 45 minutes  before meals. With the exception of having
T2DM, patients were healthy. Patients with a body mass index
(BMI) > 35 kg/m2, and those being treated with oral
anithyperglycaemic agents, systemic glucocorticoids, or insulin
doses > 2.0 U/kg were excluded.
Study design
This randomised, open-label, two-way crossover study
consisted of a 2-week lead-in and two 4-week treatment phases
(Fig. 1). Each 4-week outpatient treatment (dose-adjustment)
phase preceded a 3-day inpatient (test) phase. During the
inpatient phase, patients were hospitalised for up to 96 hours
to determine PG profiles on 3 consecutive days. The study
insulins (Eli Lilly and Company, Indianapolis, Indiana, USA)
were injected 5 minutes before  breakfast and dinner, omitting
a lunch injection, since a twice-daily insulin regimen was
investigated in this study. The ethical review board of the
University of the Free State, Bloemfontein, approved the
protocol, and all patients gave informed consent according to
Good Clinical Practice Guidelines and the Declaration of Helsinki.
Assessments
Lead-in phase
At visit 1, a comprehensive history and physical examination
was completed, blood samples were collected and study diaries
were given. Patients received 30/70 before the morning and
evening meals during the lead-in phase. The investigators
telephoned patients at least once weekly to meet target BG for
fasting and before meals (< 7.0 mmol/l) and 2 hours after
breakfast and dinner (< 10.0 mmol/l). At visit 2 patients were
randomised to Mix25 followed by 30/70, or 30/70 followed by
Mix25.
Outpatient treatment (dose-adjustment) phase
During treatment with either insulin, patients were instructed
to attempt to meet the abovementioned glycaemic goals. The
investigator contacted the patients twice weekly during each
treatment period to optimise insulin dose. 
Between visits 2 and 3, and between visits 3 and 4, patients
obtained a self-monitored BG profile twice weekly using the
BG meter provided (Accutrend alpha, Boehringer Mannheim
GmbH, Mannheim, Germany). Self-monitored BG profiles
consisted of fasting, before lunch and dinner, and 2-hour
postprandial BG after each meal. Measured BG values were
used to adjust the insulin dose. A hypoglycaemic episode was
defined as any time a patient experienced, or another person
observed a patient experiencing a self-assessed sign/symptom
associated with hypoglycaemia, or any spontaneous BG
measurement < 3.0 mmol/l (54 mg/dl). Each patient recorded
the BG level, associated symptoms, and treatment, and this
information was collected at visits 2, 3 and 4.
Between visits 2 and 3 and between visits 3 and 4, patients
were asked to reproduce the standard breakfast and dinner
meal (similar to meals during the inpatient phase) several
times at home to determine if an acceptable insulin dose had
been identified that could be used before the standard inpatient
breakfast and dinner. Although the upper limit for
postprandial BG was < 10.0 mmol/l, an ideal insulin dose
resulted in a postprandial BG < 8.0 mmol/l, and did not result
in hypoglycaemia.
Inpatient treatment (test) phase
Patients reported to the research unit on the evening before the
first day of the inpatient phase, injected either Mix25 or 30/70
and consumed a standard dinner. The following morning an
indwelling cannula was established for blood sampling. The
patient’s fasting BG was determined between 06h30 and 07h00.
If the fasting BG was > 8.0 mmol/l, a continuous intravenous
regular human insulin infusion began in order to lower the BG
to between 6.0 and 8.0 mmol/l within the following hour in
order to have similar baselines between patients. On each test
day if the target BG was not achieved before 08h00, breakfast
was delayed until the target BG was reached and time of
breakfast was noted as zero hour.
During the inpatient phase, an individualised diet providing
130 kJ (32 kcal) per kilogram ideal body weight was calculated
(50% carbohydrate, 20% protein, and 30% fat). The
carbohydrate was distributed as follows: 30% at breakfast, 30%
at lunch, and 40% at dinner. Ad libitum consumption of non-
caloric liquids (e.g. diet cola, black coffee) was allowed during
the inpatient phase, but no other food was permitted.
Patients received a standard breakfast, lunch, and dinner
between 07h00 and 08h00, 12h00 and 13h00, and 18h00 and
19h00, respectively, or later if more time was required to
achieve the baseline target BG. Both study insulins were















   
Fig. 1. Study design.
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before breakfast and dinner. Insulin dose on day 1 was based
on BG results with standard meals during the outpatient phase
and remained the same on each inpatient day. However, if the
BG profile determined on day 1 indicated that the dose was not
effective in reaching the target BG, the dose was adjusted for
day 2. In this case, insulin doses were identical on day 2 and
day 3.
Two blood samples were obtained before meals and at 
1-hour intervals thereafter. One sample of venous whole blood
collected with sodium fluoride was used for enzymatic
determination of PG and statistical analysis of the PG profiles.
The other sample of venous whole blood collected with
ethylenediamine tetraacetic acid (EDTA) was used for the
immediate determination of BG using a BG meter. If BG was <
3.0 mmol/l and/or symptoms of hypoglycaemia occurred any
time during the inpatient phase, the patient ate a standard
snack. One snack unit (three Cream Cracker biscuits, Bakers
Pty (Ltd), South Africa) provided 369 kJ  (88 kCal). If
hypoglycaemia continued, as indicated by BG measurements in
10-minute intervals until BG was > 3 mmol/l for two
consecutive measurements, one more snack was eaten. Snacks
were consumed as necessary to maintain BG > 3 mmol/l.
Following the collection of the final blood sample at 08h00
the morning after day 3 and before discharge from the research
unit, the patient was given breakfast and the first dose of study
insulin for the next treatment interval (visit 3) or the usual
(prescribed) insulin (visit 4). The study was completed the
morning after inpatient phase day 3 of visit 4.
Statistical methods
Following the intent-to-treat approach, data were used from all
randomised patients who received at least one treatment dose.
The last observation carried forward was used to impute
missing data. PG and parameters computed from PG, insulin
doses, and 30-day hypoglycaemia rate were analysed using the
crossover method described by Koch9 and Taulbee.10 Analysis
of variance models (ANOVAs) were used to examine the
carryover and treatment effect as described in Koch9 and
Taulbee.10 All tests were performed using a two-sided test with
an alpha level of 0.05.
Glucodynamic evaluations
Parameters computed from the PG measurements included 
24-hour PG profiles, and the maximum glucose concentration
(Cmax). Additional parameters based on glucose excursions
from baseline were also computed. Excursions from baseline
were defined as the baseline (time = 0) PG concentration
subtracted from each of the measured PG concentrations. Log




Of the 25 patients randomised, 21 completed the study. Four
patients discontinued the study; 3 based on the investigator’s
decision (1 patient on Mix25 and 2 patients on 30/70), and 1
based on the patient’s own decision (Mix25). There were no
differences in patients’ baseline characteristics (Table I). No
significant unequal carryover effects were observed.
There were no differences in the mean (± standard error of
the mean (SEM)) insulin doses for the two study insulins
before breakfast (Mix25 31.6 ± 3.0 units v. 30/70 32.3 ± 3.4 units,
p = 0.58) or before dinner (Mix25 26.8 ± 3.1 units v. 30/70 26.4 ±
3.2 units, p = 0.61) during the outpatient phase. During the
inpatient phase, the insulin dose was modified from day 1 to
day 2 in some patients (pre-breakfast 30/70 N = 11, Mix25 
N = 7, pre-dinner 30/70 N = 7, Mix25 N = 4). Therefore, only
data from days 2 and 3 were used for analysis of efficacy (PG),
as the protocol required insulin doses to be the same on all
inpatient test days. There were no differences in insulin doses
before breakfast (Mix25 32.4 ± 3.3 units v. 30/70 33.3 ± 3.4 units,
p = 0.169) or before dinner (Mix25 27.6 ± 3.3 units v. 30/70 27.5
± 3.2 units, p = 0.769) during days 2 and 3.
Glucodynamics
The 24-hour PG profiles for the two treatments were compared
(Fig. 2). Two-hour PG excursions following breakfast 
(p = 0.002) and dinner (p = 0.018) were significantly smaller
with Mix25 than with 30/70 (Fig. 3). Fasting, pre-lunch, and
pre-dinner PG levels were similar between treatments.
The PG AUC between breakfast and lunch was smaller with
Mix25 than with 30/70 (Mix25 77.6 ± 3.8 mmol/h/ml v. 30/70
89.5 ± 4.3 mmol/h/ml, p = 0.001). The PG AUC between lunch
and dinner (Mix25 131.7 ± 5.7 mmol/h/ml v. 30/70 132.6 ± 7.8
mmol/h/ml, p = 0.789), dinner and bedtime (Mix25 52.7 ± 3.2
mmol/h/ml v. 30/70 53.0 ± 7.8 mmol/h/ml, p = 0.975), and
bedtime and breakfast (Mix25 117.8 ± 6.5 mmol/h/ml v. 30/70
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Baseline variable (N = 13) (N = 12) p-value
Gender (M/F) 10/3 7/5 0.411
Age (yrs) 54.8 ± 1.82 53.6 ± 2.15 0.667
BMI (kg/m2) 29.2 ± 1.2 29.3 ± 1.2 0.962
HbA1C (%) 7.81 ± 0.33 7.60 ± 0.33 0.645
MF = male/female; BMI = body mass index; HbA1C = haemoglobin A1C.
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119.2 ± 9.1 mmol/h/ml, p = 0.895) were not different between
treatments.
The Cmax between breakfast and lunch was significantly
lower with Mix25 (Mix25 13.3 ± 0.6 mmol/l v. 30/70 
15.2 ± 0.7 mmol/l, p = 0.002) than with 30/70. The Cmax for the
remaining time intervals — lunch to dinner (Mix25 
13.9 ± 0.6 mmol/l v. 30/70 13.8 ± 0.8 mmol/l, p = 0.552), dinner
to bedtime (Mix25 12.2 ± 0.7 mmol/l v. 30/70 
12.9 ± 0.8 mmol/l, p = 0.212), and bedtime to breakfast (Mix25
9.5 ± 0.7 mmol/l v. 30/70 10.1 ± 0.9 mmol/l, p = 0.656) — were
not significantly different between treatments.
Hypoglycaemia
The 30-day hypoglycaemia rate was low during both the
outpatient phase (Mix25 0.049 ± 0.018 episodes/patient/30
days v. 30/70 0.100 ± 0.018 episodes/patient/30 days, p =
0.586) and the inpatient phase (Mix25 0.241 ± 0.053
episodes/patient/30 days v. 30/70 0.222 ± 0.053
episodes/patient/30 days, p = 0.524) for both treatments.
Discussion
We found that the 24-hour PG profile appeared smoother with
Mix25 than with 30/70 (Fig. 2). We attributed this to the PG
excursions following breakfast and dinner that were smaller
with Mix25 than with 30/70. Whereas the postprandial PG
excursions were improved with Mix25 because of the faster
onset of action of insulin lispro, PG in the late postprandial
phase, before meals, and throughout the night were similar
between the two study insulins. In the present study, insulin
was not administered before lunch. PG after lunch was similar
for Mix25 and 30/70. Therefore, the postprandial insulin
requirement for lunch was supplied equally by the two insulin
regimens. The rates of hypoglycaemia during the inpatient and
outpatient phases were low and did not differ between
treatments.
The present findings are in agreement with others.4,6,7 In a
previous study of T2DM patients, Mix25 provided better
postprandial BG control than either 30/70 or NPH, following a
standard test meal;6 specifically, Mix25 significantly lowered
the 4-hour glucose AUC and the maximum glucose excursion.
Malone et al.7 confirmed the findings of that study, reporting
smaller BG excursions with Mix25 following a standard test
meal in T2DM patients. Roach et al.4 also reported that twice-
daily administration of Mix25 in T2DM patients resulted in
improved postprandial glycaemia control and similar overall
glycaemic control, while providing the convenience of
administering insulin immediately before meals compared
with 30/70. The present study agrees with these previous
findings and provides further evidence supporting the use of
Mix25 in T2DM patients. 
Increasing evidence supports the significance of postprandial
BG and the importance of its control in preventing some of the
long-term complications associated with diabetes. 11-13 Therefore,
treatment regimens that provide superior postprandial control
become increasingly important. Indeed, the Diabetes Control
and Complications Trial Research Group (DCCT) investigators
speculated that ‘mean HbA1c is not the most complete
expression of the degree of hyperglycaemia. Other features of
diabetic glucose control, which are not reflected by HbA1c, may
add to or modify the risk of complications. For example, the
risk of complications may be more highly dependent on the
extent of postprandial glycemic excursions.’ 14
A possible limitation of the present study was that both
study insulins were injected 5 minutes before breakfast and
dinner; however, evidence suggests that injecting insulin close
to the time of eating is the practice of the majority of patients.15
It is recommended that 30/70 be injected 30 minutes before









     


























Fig. 3. 2-hour plasma glucose excursions following breakfast and
dinner on inpatient days 2 and 3.
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30/70 in the present study, the difference between the effects of
the two study insulins might have been less pronounced.
However, the timing of injection used in the present study was
considered to be a more realistic approach based on clinical
experience. It may be of interest to re-examine the research
question including a separate arm of the study with a 30-
minute pre-meal injection of 30/70.
Conclusion
Mix25 provided a smoother 24-hour PG profile with smaller
PG excursions following breakfast and dinner compared with
30/70. The rate of hypoglycaemia throughout the study was
low  and not significantly different for the two study insulins.
Therefore, Mix25 is a valuable treatment option for patients
with T2DM.
This work was sponsored by Eli Lilly and Company.
Appreciation is expressed to Peggy Campbell for her expert
editorial assistance with the manuscript.
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